Skip to main content

A tale of two opioid antidotes

Delivered every Tuesday and Friday by 12 p.m., Prescription Pulse examines the latest pharmaceutical news and policy.
Aug 09, 2024 View in browser
 
POLITICO's Prescription Pulse newsletter logo

By Lauren Gardner

Driving the day

A naloxone kit is pictured.

The FDA approved on Aug. 7 an alternate opioid overdose reversal injection to naloxone, pictured here. | Andrew Burton/Getty Images


NEW OVERDOSE REVERSAL MED — The FDA this week approved a new product to reverse opioid overdoses, but some harm-reduction experts say it’s an unnecessary tool that could pose more risks than benefits.

The FDA late Wednesday approved Zurnai, an autoinjector made with nalmefene, which is a longer-acting chemical cousin of the gold-standard reversal-drug naloxone. The drug is available by prescription only and is indicated for people age 12 and older suspected or known to be suffering an opioid overdose.

"The FDA remains focused on broadening access to opioid overdose reversal agents, including naloxone and nalmefene,” Commissioner Robert Califf said in a statement.

Others urge caution: But Mike Selick, associate director of capacity building at the National Harm Reduction Coalition, said there’s no need for Zurnai because naloxone is proven effective at reversing overdoses caused by heroin, fentanyl and its analogs. The best response to a known or suspected overdose, he added, is to use the lower dose of naloxone with rescue breathing.

“Higher dose reversal drugs and long acting reversal drugs put people who are dependent on opioids into longer and more severe withdrawal,” he told Prescription Pulse in an email. “This makes people less likely to seek further care and more likely to try and use more opioids which can result in another overdose.”

Background: Selick’s position mirrors a statement issued last year by the American College of Medical Toxicology and the American Academy of Clinical Toxicology, months after the FDA approved a nalmefene-based nasal spray.

Even then, nalmefene wasn’t a new drug — the FDA approved it in 1995 as an injectable opioid antidote. The manufacturer pulled it from the market in 2008 for commercial reasons.

“The longer duration of action of nalmefene does not eliminate the need for medical observation after administration,” the two groups said in the statement. “We are concerned that the long duration of action may provide a false sense of comfort that no further care is needed.”

If a patient receives nalmefene in an emergency room, they said, the drug’s administration could spur a longer stay, thus stressing resources.

Another wrinkle: Zurnai is made by a well-known name in the opioid space: Purdue Pharma. The company, which is blamed for fueling the rise of the opioid epidemic by pushing addictive painkiller prescriptions, said in a statement it’s “working to provide Zurnai at no profit to the Company.”

IT’S FRIDAY. WELCOME BACK TO PRESCRIPTION PULSE. Your host hopes D.C.-area native Noah Lyles recovers from Covid soon (and notes that she would not be winning any Olympic medals if she were scheduled to race while sick).

Send tips to David Lim (dlim@politico.com or @davidalim) and Lauren Gardner (lgardner@politico.com or @Gardner_LM).

 

During unprecedented times, POLITICO Pro Analysis gives you the insights you need to focus your policy strategy. Live briefings, policy trackers, and and people intelligence secures your seat at the table. Learn more.

 
 
Drug Pricing

JUDGE DISMISSES CHAMBER IRA CASEDistrict Court Judge Michael J. Newman rejected the U.S. Chamber of Commerce’s challenge to Medicare drug price negotiations on Thursday, taking issue with what he termed the group’s attempt to venue shop for a favorable opinion.

Newman, who was appointed by former President Donald Trump, determined that the three other groups party to the chamber’s lawsuit — all state or local chambers representing Michigan and Ohio — didn’t have standing to bring the case before the Ohio Southern District. He found the U.S. Chamber “may plausibly have standing” but that his court was the wrong venue.

Sharp words: Newman addressed one of the biggest critiques leveled against the pharma industry allies that have sued over the program in courts nationwide — that they’re angling for favorable rulings in historically conservative jurisdictions to split from anticipated dismissals in other courts hoping to elevate their cause to the Supreme Court.

“If the Court found the Dayton Area Chamber of Commerce had standing in this case, it would open the door for any individual or company to bypass venue rules by becoming a member of any association remotely related to a challenged law or regulation,” Newman wrote. “The Court will not adopt a loose interpretation of the standing requirement for the purpose of forum shopping.”

Next steps: A chamber spokesperson said the group is weighing its next move as it reviews the decision. It’s the seventh case to be rejected at the district court level; two lawsuits — Merck’s and Novartis’ — are awaiting decisions.

Industry Intel

David Ricks speaks.

Eli Lilly CEO David Ricks speaks at the Economic Club of New York on March 12, 2024, in New York. The U.S. drugmaker, which makes popular drugs for weight loss and diabetes, saw a 36 percent revenue increase in the second quarter of 2024 compared with the same time last year, in part due to those medications. | Spencer Platt/Getty Images

GLP-1s BOOST LILLY EARNINGSEli Lilly posted a 36 percent revenue jump in the second quarter of 2024 compared with the same time last year, the company said Thursday, a jump it attributed in part to GLP-1 diabetes and weight-loss brands Mounjaro and Zepbound.

Production increases for those drugs helped promote sales growth, Lilly said, but it still anticipates “periodic supply tightness” for certain dosages as demand increases. While all dosages of the two drugs were considered available in the U.S. as of Aug. 2, the FDA hasn’t removed them from its drug shortage list as it evaluates various market dynamics to determine whether back orders can be filled and the company can consistently meet demand.

CEO Dave Ricks said the production increase will translate to patients likely having to wait a few days to get their prescriptions filled but suggested that doesn’t mean the drugs are still in shortage.

“We're doing well, given the situation, but the end pharmacy experience will continue to be choppy. We point that out to the FDA,” he said. “So that means people may call and say, ‘I couldn't get what I wanted the moment I wanted it at the pharmacy I choose to [use].’ That's not the definition that we think applies here. So we'll continue to work with channel partners and the agency to try to clear up the confusion and improve the consumer experience, which is our responsibility along with theirs.”

Compounding concerns: Executives said Lilly’s primary concern with compounding pharmacies trying to meet demand is patient safety rather than lost market share. Compounding groups have argued that products made by legitimate pharmacies are subject to rigorous standards.

Ricks attributed GLP-1 shortages to industry manufacturing constraints around sterile injectable drugs and indicated the company will continue its political and legal advocacy targeting compounders.

AROUND THE AGENCIES

MEDICARE DEVICE PATHWAY — CMS finalized a long-awaited rule Wednesday creating a pathway for Medicare to cover some FDA-designated breakthrough medical devices after the White House rescinded a Trump-era regulation, Chelsea and Ben report.

Industry reaction to the rule was mixed, with some groups saying it didn’t go far enough by excluding diagnostics and limiting eligibility to five devices per year.

Pharma Moves

Dr. Amanda Banks will be chief development officer at Ovid Therapeutics, a biotech company focused on treatments for rare epilepsies and brain conditions. She previously co-founded and was the CEO of Blackfynn, a data platform company developing neurological disease therapies.

 

SUBSCRIBE TO GLOBAL PLAYBOOK: Don’t miss out on POLITICO’s Global Playbook, our newsletter taking you inside pivotal discussions at the most influential gatherings in the world. Suzanne Lynch delivers the world's elite and influential moments directly to you. Stay in the global loop. SUBSCRIBE NOW.

 
 
WHAT WE'RE READING

HHS has yet to finalize guidelines for its employees at public health agencies like the CDC and the FDA to report political interference two years after a government watchdog recommended them, POLITICO’s Sophie Gardner reports.

Drugmakers and their allies are ramping up lawsuits challenging state laws forbidding them from limiting supply of discounted drugs to certain pharmacies under the 340B safety-net program for lower-income patients, Bloomberg Law writes.

 

Follow us on Twitter

David Lim @davidalim

Lauren Gardner @Gardner_LM

 

Follow us

Follow us on Facebook Follow us on Twitter Follow us on Instagram Listen on Apple Podcast
 

To change your alert settings, please log in at https://login.politico.com/?redirect=https%3A%2F%2Fwww.politico.com/settings

This email was sent to rouf@idiot.cloudns.cc by: POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA

Unsubscribe | Privacy Policy | Terms of Service

Comments

Popular Posts

Can’t get no satisfaction

Presented by Electronic Payments Coalition: Shia Kapos' must-read rundown of political news in the Land of Lincoln Jun 28, 2024 View in browser   By Shia Kapos Presented by  ...

Want to win $100? Who doesn't!

Anyone can win up to $100 when they play this game. They make ALL the choices. They even get to set the game up any way they like!!  But no matter how clever they are, you win every time. Watch a FULL performance here: https://www.penguinmagic.com/p/16416 Here's what happens: 1. You set up a board with 6 spaces lettered A-F. 2. Your spectator decides where to put 6 different prizes: ($1, $5, $10, $20, $50 and $100).  It's a genuine free choice. 3. When they're satisfied, you reveal the steps of the ga...

Israel helps U.S. avoid cyberattack / NATO launching cyber rapid response force / Lazarus believed to have hacked Horizon

Plus: Amazon patches high-severity bug Inside.com Part of   Network June 30, 2022 Presented by Israel's IDF Unit 8200 helped stop a cyberattack on U.S. power plants. The announcement was made by the deputy chief of Unit 8200. More: IDF members realized that an attack on the U.S. power plants was brewing while they fought attacks on Israel's water system. The unit then informed law authorities in the U.S. The rest of the details were not presented due to the classified nature of the information, but similar attacks throughout the world have shown that energy remains one of the most targeted sectors by hackers. IDF Unit 8200 is the military intelligence unit of the IDF. The unit is highly secretive and consists of the most elite cyber specialists in Israel. Zoom Out: Israel's intelligence authorities have previously warned the U.S of other cyber...

Breaking News: Justice Department charges DePape following Paul Pelosi assault

The Justice Department on Monday charged David DePape with assault and attempted kidnapping following his alleged break-in at the home of Speaker Nancy Pelosi and her husband Paul. Paul Pelosi was hospitalized after DePape allegedly struck him with a hammer early Friday morning. Police tackled DePape after arriving on the scene, where officers found a roll of tape, white rope, a second hammer, gloves and zip ties, DOJ said Monday. DePape called out for Nancy Pelosi during the break-in, according to law enforcement officials — an echo of rioters' vocal search for the speaker during the Jan. 6 Capitol siege. The kidnapping charge carries a maximum sentence of 20 years in prison, and the assault charge carries a maximum sentence of 30 years. Read the latest To change your alert settings, please go to https://www.politico.com/_login?base=https%3A%2F%2Fwww.politico.com/settings .. This email was se...

Breaking News: Senate Republicans nudge Trump's trade chief for a tariff end game

Senate Republicans nudge Trump's trade chief for a tariff end game Breaking News Alert ...

Supercell ID Login [014 987]

014 987 - Use the verification code below to log in. ...

Breaking News: Appeals court clears way for Trump to restart mass firings of probationary workers

Appeals court clears way for Trump to restart mass firings of probationary workers Breaking News Alert ...

IN STOCK: "I freaking love this routine - I do it all the time!" -Dan Sperry, Illusionists, AGT

Watch a performance: https://www.penguinmagic.com/p/17842 "I've been a professional magician for over 50 years, and I've seen it all. I've only written 3 reviews. This is my 4th and for good reason. As far as getting deeply emotional reactions, this trick is the easiest way to do it. And every single time it has never failed to garner the reactions shown in the trailer." - Larry Kugelman ...

πŸ“„ Al Fahad Al Fahad posted an update

  πŸ€£πŸ˜‚           Facebook                 πŸ“„ Al Fahad Al Fahad posted an update. 30 April at 22:47   View Status               This message was sent to ludomallam@idiot.cloudns.cc . If you don't want to receive these emails from Facebook in the future, please unsubscribe . Facebook, Inc., Attention: Community Support, 1 Facebook Way, Menlo Park, CA 94025         To help keep your account secure, please don't forward this email. Learn more.      

"This will fool you." -John Bannon (and he's right!)

One of my all-time favorite tricks, this one fooled me BADLY, and it'll fool you too. The secret is so clever, so fool-proof, it caught me completely by surprise. It takes zero skill, and works every time.   Before you watch:  Keep in mind the spectator shuffles the deck thoroughly, and fairly immediately before the trick starts -- you never rearrange their order! https://www.penguinmagic.com/p/13384 You're about to play a game.. and predict the outcome. 1. Your  spectator thoroughly shuffles the deck, an...